Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study-Reference-Cited by-同舟云学术

Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study

Published:2021-10-26 Issue: Volume: Page:
ISSN:1052-9276
Container-title:Reviews in Medical Virology
language:en
Short-container-title:Reviews in Medical Virology

Author:

Abdoli Asghar¹²^ORCID,Aalizadeh Reza³,Aminianfar Hossein⁴,Kianmehr Zahra⁵,Teimoori Ali⁶,Azimi Ebrahim⁷,Emamipour Nabbi⁷,Eghtedardoost Marzieh⁸,Siavashi Vahid⁹,Jamshidi Hamidreza¹⁰,Hosseinpour Mohammadreza¹¹,Taqavian Mohammad¹¹,Jalili Hasan¹²

Affiliation:

1. Department of Hepatitis and AIDS Pasteur Institute of Iran Tehran Iran

2. Amirabad Virology Laboratory Vaccine Unit Tehran Iran

3. Biochemistry Department Faculty of Biological Science Tarbiat Modares University Tehran Iran

4. Institute of Biomedical Research University of Tehran Tehran Iran

5. Department of Biochemistry Faculty of Biological Science Islamic Azad University North Tehran Branch Tehran Iran

6. Department of Virology Faculty of Medicine Hamadan University of Medical Sciences Hamadan Iran

7. Department of Biotechnology Darou Pakhsh Pharmaceutical Co. Tehran Iran

8. Arena Diagnostics, Ltd. Tehran Iran

9. Azma Teb Gostar Sorena Research Company Basic Medical Science Research Center Tehran Iran

10. Department of Pharmacology Faculty of Medicine Shaheed Beheshti University of Medical Sciences Tehran Iran

11. Research and Development Unit Biosunpharmed Co Karaj Iran

12. Department of Life Science Engineering Faculty of New Sciences and Technologies University of Tehran Tehran Iran

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rmv.2305

Reference55 articles.

1. History of vaccination

2. Immunological considerations for COVID-19 vaccine strategies

3. Safety and immunogenicity of a QazCovid‐in® inactivated whole‐virion vaccine against COVID‐19 in healthy adults: a randomized, single‐blind, placebo‐controlled phase 1 clinical trial with a 6 months follow‐up and an open‐label phase 2 clinical trial in Kazakhstan;Zakarya K;Lancet Infect Dis,2021

4. Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome

5. Vaccine Analysis: Strategies, Principles, and Control

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 Vaccines: Where Did We Stand at the End of 2023?;Viruses;2024-01-29

2. Evaluation of Stability, Inactivation, and Disinfection Effectiveness of Mpox Virus;Viruses;2024-01-11

3. Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model;Scientific Reports;2024-01-02

4. Thematic analysis of Direct-To-Consumer Advertising (DTCA) for vaccination campaigns during the COVID-19 pandemic: Healthcare experts’ insights;Journal of Marketing Communications;2023-12-04

5. Humoral immunogenicity assessment after receiving three types of SARS-CoV-2 vaccine;Scientific Reports;2023-11-18